Syneron Bio (元思生肽)
Beijing macrocyclic-peptide company whose Synova platform drew an AstraZeneca deal worth up to US$3.4B, plus ~US$250M in venture funding.
1. Core Product / Service
Syneron Bio was founded in March 2022 [6] and is based in Beijing. It develops macrocyclic peptides, including oral ones. Its engine is Synova™, which the company describes as an intelligent, high-throughput macrocyclic-peptide R&D platform [3][4]. Target areas are oncology, autoimmune, metabolic and rare diseases [1].
Pipeline. The company describes a diversified pipeline but has not named candidates or stages. The March 2026 Series B is earmarked partly for "advancing the pipeline toward the clinic", which implies no asset is yet in human trials [1].
Wet-lab model. Syneron says Synova is high-throughput, and AstraZeneca deal proceeds were to fund an expansion of its Beijing R&D center [3]. That points to in-house experimental capacity. The synthesis and selection technology (for example display methods, DNA-encoded libraries or automated solid-phase synthesis), lab size and headcount are not disclosed. No job postings were found.
2. Target Users & Pain Points
- Big pharma seeking oral peptides. Macrocycles can reach targets that small molecules cannot drug, but oral bioavailability and permeability are hard to engineer. AstraZeneca bought access to the platform for chronic diseases [3][4].
- Its own pipeline. Following the 2026 Series B, the internal assets are meant to become the company's main value driver.
3. Competitive Landscape
| Player | Positioning | Vs. Syneron |
|---|---|---|
| pinnacle-medicines | 2024 Shanghai/US oral-peptide startup | Younger; plans first-in-human in late 2026 |
| ligit-pharma | 2026 Tsinghua AIR peptide spin-out | Seed stage; similar AI + peptide thesis |
| aipher | Tsinghua AIR small-molecule and peptide startup | Earlier, academic wet-lab partners |
| helixon-therapeutics | Same-cohort AI antibody company | Biologics, not peptides; already sells assets |
4. Unique Observations
- The pharma deal is for the platform, not an asset. AstraZeneca paid for Synova access and co-development rights, then led the A/A+ round [3][5]. That validates the platform and its data, but not yet any specific Syneron molecule.
- Capital arrived fast. Close to US$100M in A/A+ in December 2025 and US$150M in Series B four months later [1][5]. Existing investors include AstraZeneca, Lilly Asia Ventures, Hillhouse (GL Ventures) and 5Y Capital.
- Disclosure is thin for its funding size. There is no named lead asset, and no public founder biography or lab description.
5. Financials / Funding
| Round | Date | Amount | Investors |
|---|---|---|---|
| Early rounds | 2022–2024 | not disclosed | Early backers reportedly include 5Y Capital, GL Ventures, Innovation Works, Lenovo Capital [1] |
| Series A + A+ | Dec 2025 | ~US$100M | Led by AstraZeneca, the AstraZeneca-CICC fund and a top healthcare fund; Pfizer-backed Biotech Development Fund, GL Ventures, 5Y, Innovation Works, Lenovo Capital participated [5] |
| Series B | 31 Mar 2026 | US$150M | Led by an unnamed international biotech fund, co-led by Dechen Capital and CDH VGC; an ADIA subsidiary, Temasek-backed Ming Capital, Qiming, Boyuan followed; AstraZeneca and Lilly Asia Ventures re-invested [1][2] |
- Total raised (disclosed): about US$250M.
- AstraZeneca collaboration (March 2025): US$75M in upfront and near-term milestones, up to US$3.4B in development and commercial milestones, tiered royalties, plus an equity investment [3][4]. One Chinese summary splits this as US$55M upfront and up to US$75M near-term [6]; the press releases give US$75M as the combined figure.
6. People & Relationships
- Founder & CEO: 张骁 (Xiao Zhang) [1]. Background is not publicly detailed.
- Strategic partner and investor: AstraZeneca.
- Investors: Lilly Asia Ventures, Qiming, Temasek's Ming Capital, CDH VGC, Dechen Capital, 5Y Capital.
- Peers: helixon-therapeutics, metis-techbio, stonewise, mindrank, revir-therapeutics.
Sources
- PEdaily (Series B) — https://news.pedaily.cn/202603/562257.shtml
- Zhong Lun — https://www.zhonglun.com/news/trade/55853.html
- China.com Tech (AstraZeneca deal) — https://m.tech.china.com/articles/20250322/202503221651482.html
- Contract Pharma — https://contractpharma.com/breaking-news/syneron-bio-astrazeneca-partner-to-develop-macrocyclic-peptides
- The Pharma Letter (A/A+) — https://www.thepharmaletter.com/pharma-news/astrazeneca-backs-syneron-bio-in-near-100m-financing
- 36Kr EU — https://eu.36kr.com/zh/p/3991520602585859